Treace Medical Concepts Financials - Benzinga

Treace Medical Concepts Inc

TMCINASDAQ

Trade with Public

Trade with Public

$4.67

0.020.43%

Last update: Aug 31, 12:25 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Treace Medical Concepts Financials

Treace Medical Concepts (TMCI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Treace Medical Concepts Q2 EPS $(0.24) Beats $(0.30) Estimate, Sales $45.376M Beat $44.020M Estimate

Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.30) by 20 percent. This is a 14.29 percent increase over losses of $(0.28) per share

Benzinga Newsdesk

PRO
Treace Medical Concepts Raises FY2026 Sales Guidance from $202.000M-$212.000M to $204.000M-$212.000M vs $206.220M Est

Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $202.000 million-$212.000 million to $204.000 million-$212.000 million vs $206.220 million estimate.

Benzinga Newsdesk

PRO
Treace Medical Concepts Raises FY2026 Sales Guidance from $200.000M-$212.000M to $202.000M-$212.000M vs $205.920M Est

Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $200.000 million-$212.000 million to $202.000 million-$212.000 million vs $205.920 million estimate.

Benzinga Newsdesk

PRO
Treace Medical Concepts Q1 EPS $(0.28) Beats $(0.31) Estimate, Sales $47.198M Beat $45.960M Estimate

Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 12 percent decrease over losses of $(0.25) per share

Benzinga Newsdesk

PRO
Treace Medical Concepts Sees FY2026 Sales $200.000M-$212.000M vs $210.335M Est

2026 Financial OutlookThe Company is initiating full-year 2026 revenue guidance of $200 million to $212 million representing a decline of 6% to 0% compared to full-year 2025.The Company expects a loss in Adjusted EBITDA

Benzinga Newsdesk

Treace Medical Concepts Q4 Earnings Summary & Key Takeaways

Benzinga Insights